Flexible-Dose Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TemPo-3)

  • days left to enroll
  • participants needed
  • sponsor
    Cerevel Therapeutics, LLC
Updated on 31 March 2022
mao-b inhibitor


The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are experiencing motor fluctuations.


Condition Parkinson's disease
Treatment Placebo, Tavapadon
Clinical Study IdentifierNCT04542499
SponsorCerevel Therapeutics, LLC
Last Modified on31 March 2022


Yes No Not Sure

Inclusion Criteria

Sexually active men or women of childbearing potential must agree to practice effective birth control, or remain abstinent during the trial and for 4 weeks after the last dose of trial treatment
Participants who are capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
Participants who are able, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures
Participants with a diagnosis of PD that is consistent with the UK Parkinson's Disease Society Brain Bank diagnostic criteria, with bradykinesia and motor asymmetry
Participants with modified Hoehn and Yahr stage 2, 2.5, or 3 in the "on" state
Participants with a good response to L-Dopa in the judgment of the investigator
Participants who return a completed self-reported home diary for motor function status (Hauser diary) during the screening period (after diary training and concordance testing has occurred), with recordings for 2 consecutive days (ie, 2 consecutive 24-hour periods) showing at least 2 and half hours of "off" time on each of the 2 days
Participants who are on a stable dose of L-Dopa for at least 4 weeks prior to screening and are taking a minimum total daily dose of 400 milligram (mg) divided in at least 4 doses per day of standard carbidopa/levodopa or divided in at least 3 doses per day of extended-release carbidopa/levodopa capsules. The carbidopa/levodopa dose and frequency must be maintained for the duration of the trial
Prior and concurrent use of catechol-O-methyl transferase (COMT) inhibitors, monoamine oxidase (MAO-B) inhibitors, amantadine, or anticholinergic drugs is permitted if use was initiated greater than (>) 90 days before signing of the informed consent, the dosage has remained stable for a minimum of 4 weeks before signing of the informed consent, and the dosage will remain stable for the duration of the trial (ie, no change in the COMT, MAO-B inhibitor, or amantadine dose is permitted during the trial)

Exclusion Criteria

Participants with a history or clinical features consistent with essential tremor, atypical or secondary parkinsonian syndrome (including, but not limited to, progressive supranuclear palsy, multiple system atrophy, cortico-basal degeneration, or drug-induced or poststroke parkinsonism)
Participants with a history of nonresponse or insufficient response to L-Dopa at therapeutic dosages
Participants who have had previous surgical intervention (eg, deep brain stimulation) for PD or for whom such a procedure is planned or anticipated during the trial period
Participants with an acute or chronic, clinically significant medical or psychiatric condition, cognitive impairment, or laboratory abnormality that might increase the risk associated with trial participation or administration of trial treatment or interfere with the interpretation of the trial results or that, in the judgment of the investigator, would make the Participant inappropriate for entry into this trial.- Medical conditions that are minor or well controlled may be considered acceptable if the condition does not expose the Participant to an undue risk of a significant AE or interfere with the assessments of safety or efficacy during the course of the trial. Participants with symptoms of anxiety or depression that are not debilitating and that are stable or adequately controlled with non-prohibited medication are considered acceptable. The medical monitor should be contacted in any instance where the investigator is uncertain regarding the stability of a Participant's medical conditions(s) and the potential impact of the condition(s) on trial participation
Participants with a history or current diagnosis of a clinically significant impulse control disorder (Disruptive, Impulse Control, and Conduct Disorder per DSM-5) (American Psychiatric Association, 2013)
Participants with the presence of or history of brain tumor, hospitalization for severe head trauma, epilepsy (as defined by the International League Against Epilepsy), or seizures
Participants with a history of psychosis or hallucinations within the previous 12 months
Participants who answer "yes" on the Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting the criteria for C-SSRS Item 4 or Item 5 occurred within the last 6 months, OR Participants who answer "yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting the criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR Participants who, in the opinion of the investigator, present a serious risk of suicide
Participants with substance abuse or dependence disorder, including alcohol, benzodiazepines, and opioids, but excluding nicotine, within the past 6 months (180 days)
Participants with dementia or cognitive impairment that, in the judgement of the investigator, would exclude the Participant from understanding the ICF or participating in the trial
Participants with any condition that could possibly affect drug absorption, including bowel resections, bariatric weight loss surgery, or gastrectomy (this does not include gastric banding)
Participants who have a positive result for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV) antibodies at screening
Participants with a history of malignancy other than
Non-metastatic basal or squamous cell carcinoma of the skin or carcinoma in situ that was surgically removed in total >1 year before signing the ICF and had not recurred
Another type of malignancy that had been in remission for 5 years before signing the ICF and had not recurred
Participants with a history of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias that are not controlled with medical and/or surgical intervention; second- or third-degree atrioventricular block; sick sinus syndrome; severe or unstable angina; or congestive heart failure within the last 12 months. A recent (less than or equal to [<=12] months) history of myocardial infarction with secondary arrhythmias is exclusionary regardless of the therapeutic control
Participants with a history of neuroleptic malignant syndrome
Female Participants who are breastfeeding and/or who have a positive pregnancy test result prior to receiving IMP
Participants who are currently receiving moderate or strong cytochrome P450 (CYP) 3A4 inducers or CYP3A4 inhibitors (except for topical administration)
Participants with a positive urine drug screen for illicit drugs are excluded and may not be retested or rescreened. Participants with a positive urine drug screen resulting from use of marijuana (any tetrahydrocannabinol-containing product), prescription, or over-the-counter medications or products that, in the investigator's documented opinion, do not signal a clinical condition that would impact the safety of the Participant or interpretation of the trial results may continue evaluation for the trial following consultation and approval by the medical monitor
Participants who are using any prohibited medication during the trial within at least 4 weeks or 5 half-lives (whichever is greater) prior to signing the ICF
Participants with a Montreal Cognitive Assessment (MoCA) score <26
Participants with a sitting blood pressure greater than or equal to (>=) 160 millimeter of Hg (mmHg) (systolic) or >=100 mmHg (diastolic) on a single measurement. If abnormal, up to 2 repeat measurements are permitted after at least 5 minutes of rest
Participants with clinically significant orthostatic hypotension (eg, syncope)
Participants with a 12-lead ECG demonstrating a QTcF interval >450 msec (average of 3 ECGs obtained at the Screening Visit)
Participants with moderate or severe renal impairment (creatinine clearance as estimated by Cockcroft-Gault formula <30 milliliter per minute [mL/min] or on dialysis)
Participants with any of the following abnormalities in clinical laboratory tests at the Screening Visit, as assessed by the central laboratory and confirmed by a single repeat measurement, if deemed necessary
AST or ALT >=3 Upper Limit Normal (ULN)
Total bilirubin >=1.5 ULN. Participants with a history of Gilbert's syndrome may be eligible provided they have a value <ULN for direct bilirubin
Participants with other abnormal laboratory test results, vital sign results, or ECG findings unless, in the judgment of the investigator, the findings are not medically significant and would not impact the safety of the Participants or the interpretation of the trial results. The medical monitor should be contacted to discuss individual cases, as needed. Tests with exclusionary results should be repeated to ensure reproducibility of the abnormality before excluding a Participant based on the criteria provided in the protocol. For ECGs, 3 consecutive recordings are required and if 2 of the 3 remain exclusionary, then the Participant is not eligible for the trial
Participants who previously participated in any tavapadon trial, including this trial, and received investigational medicinal product (IMP)
Participants who received treatment with any other investigational drug within 60 days before signing the ICF
Any Participant who, in the opinion of the sponsor, investigator, or medical monitor, should not participate in the trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note